Tier 2 — strong

The Effects of Coenzyme Q10 Supplementation on Blood Pressures Among Patients with Metabolic Diseases: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Reza Tabrizi, Maryam Akbari, Nasrin Sharifi, Kamran B Lankarani, Mahmood Moosazadeh, Fariba Kolahdooz, Mohsen Taghizadeh, Zatollah Asemi
High Blood Pressure & Cardiovascular Prevention 2018 25(1):41-50

Bibliography

PubMed
PMID 29330704
DOI
10.1007/s40292-018-0247-2
Funding
Specific funding information was not identified in the accessible PubMed record reviewed during this audit.
Competing interests
Specific competing-interest disclosures were not identified in the accessible PubMed record reviewed during this audit.

Study snapshot

DesignSystematic review and meta-analysis of randomized controlled trials
ModelPatients with metabolic diseases receiving CoQ10 supplementation versus control.
Sample17 randomized controlled trials; 684 participants.
InterventionCoQ10 supplementation versus placebo/control; doses and durations varied across trials.
DurationVaried across included trials.
EndpointsSystolic blood pressure; Diastolic blood pressure; Subgroup effects; Heterogeneity

What the study showed, in plain terms

This 2018 meta-analysis pooled 17 randomized trials in people with metabolic diseases. CoQ10 produced a small but statistically significant improvement in systolic blood pressure, while the pooled diastolic effect was not significant.

Because the review used standardized mean differences and mixed several metabolic populations, it supports a directional systolic signal rather than a simple millimeter-of-mercury prediction for every patient with hypertension.

Key findings

Systolic blood pressure favored CoQ10: standardized mean difference -0.30 (95% CI -0.52 to -0.08).

Diastolic blood pressure was not significantly changed: standardized mean difference -0.08 (95% CI -0.46 to +0.29).

What this study can and cannot tell us

The included trials mixed different metabolic diseases, doses, formulations and treatment durations.

A standardized mean difference is less intuitive clinically than a direct millimeter-of-mercury estimate.

The result does not establish that CoQ10 prevents cardiovascular events or can replace antihypertensive therapy.

Citation network

Articles citing this research paper

1 article

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology